Maven Securities LTD Buys 27,417 Shares of Celgene Co. (NASDAQ:CELG)

Maven Securities LTD grew its stake in shares of Celgene Co. (NASDAQ:CELG) by 685.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The fund owned 31,417 shares of the biopharmaceutical company’s stock after buying an additional 27,417 shares during the quarter. Celgene makes up 1.9% of Maven Securities LTD’s holdings, making the stock its 18th biggest holding. Maven Securities LTD’s holdings in Celgene were worth $2,897,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in the company. Oregon Public Employees Retirement Fund grew its stake in Celgene by 4.6% during the second quarter. Oregon Public Employees Retirement Fund now owns 273,716 shares of the biopharmaceutical company’s stock worth $25,302,000 after purchasing an additional 12,071 shares during the period. Gilman Hill Asset Management LLC increased its stake in shares of Celgene by 18.6% in the 2nd quarter. Gilman Hill Asset Management LLC now owns 7,416 shares of the biopharmaceutical company’s stock valued at $686,000 after acquiring an additional 1,165 shares in the last quarter. Canyon Capital Advisors LLC bought a new stake in shares of Celgene in the 1st quarter valued at $119,226,000. Ruffer LLP acquired a new position in shares of Celgene during the 1st quarter valued at $226,613,000. Finally, Gyroscope Capital Management Group LLC lifted its position in shares of Celgene by 583.1% during the 2nd quarter. Gyroscope Capital Management Group LLC now owns 104,263 shares of the biopharmaceutical company’s stock valued at $9,769,000 after acquiring an additional 89,000 shares during the period. Institutional investors own 72.51% of the company’s stock.

CELG has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 price target for the company in a report on Tuesday, July 23rd. BidaskClub lowered shares of Celgene from a “buy” rating to a “hold” rating in a report on Saturday. ValuEngine cut shares of Celgene from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 1st. Mizuho downgraded Celgene from a “buy” rating to a “neutral” rating and reduced their target price for the company from $103.00 to $100.00 in a research note on Monday, August 19th. Finally, Cowen reaffirmed a “hold” rating and issued a $102.00 target price on shares of Celgene in a research report on Tuesday, July 30th. One investment analyst has rated the stock with a sell rating, eighteen have issued a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $94.60.

Shares of CELG traded up $0.69 on Wednesday, reaching $98.34. The company’s stock had a trading volume of 265,008 shares, compared to its average volume of 2,991,092. The company has a current ratio of 3.44, a quick ratio of 3.32 and a debt-to-equity ratio of 1.97. Celgene Co. has a twelve month low of $58.59 and a twelve month high of $98.97. The stock has a market capitalization of $68.80 billion, a PE ratio of 12.93, a PEG ratio of 0.45 and a beta of 1.41. The firm has a fifty day moving average of $94.75 and a 200-day moving average of $93.33.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.44 by $0.17. The business had revenue of $4.40 billion for the quarter, compared to analysts’ expectations of $4.22 billion. Celgene had a net margin of 32.24% and a return on equity of 89.93%. The firm’s revenue for the quarter was up 15.4% compared to the same quarter last year. During the same quarter last year, the firm earned $2.16 EPS. As a group, equities analysts anticipate that Celgene Co. will post 9.96 EPS for the current fiscal year.

Celgene Company Profile

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Further Reading: Growth Stocks, What They Are, What They Are Not

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.